{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:34:38Z","timestamp":1790739278366,"version":"4.1.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000043","name":"AACR","doi-asserted-by":"publisher","award":["SU2C-AACR-CT03-16"],"award-info":[{"award-number":["SU2C-AACR-CT03-16"]}],"id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Sharp & Dohme LLC"},{"name":"Merck & Co., Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Lessons learned<\/jats:title>\n                    <jats:p>Intravenous paricalcitol did not improve the efficacy of pembrolizumab, likely related to the short half-life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunotherapy has limited benefit in the treatment of advanced pancreatic cancer with the tumor microenvironment playing a key role in immune resistance. In preclinical studies, vitamin D receptor (VDR) agonists have been shown to sensitize pancreatic tumors to PD-1 blockade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a randomized, double-blinded, placebo-controlled, phase II trial to evaluate pembrolizumab with or without paricalcitol as maintenance therapy for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Participants were \u226518 years; histologically or cytologically confirmed metastatic PDAC showing no disease progression after frontline systemic therapy, and achieving maximal cytoreduction (eg, with no further antitumor effect), Eastern Cooperative Oncology Group (ECOG) status of 0 or 1; adequate organ function. Study treatment included: pembrolizumab 200\u00a0mg IV every 3 weeks and either paricalcitol 25 mcg IV 3 times per week or placebo. The primary objective was to evaluate 6-month progression free survival (PFS). Secondary objectives include evaluating the toxicity of the combination and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There was no significant difference in 6-month PFS, median PFS, median OS, nor treatment-related AEs between the 2 arms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>Paricalcitol did not improve the efficacy of pembrolizumab likely related to its short half-life of only 5-7 hours. Microbiome analysis revealed significant difference between long-term (&amp;gt;12 weeks) and short-term (&amp;lt;12 weeks) survival groups across treatment arms. Modulation of the tumor microenvironment will likely require more sustained VDR activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>Clinicaltrials.gov, ID: NCT03331562.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae323","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T15:22:33Z","timestamp":1731597753000},"source":"Crossref","is-referenced-by-count":14,"title":["Pembrolizumab \u00b1 paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9475-808X","authenticated-orcid":false,"given":"Vincent","family":"Chung","sequence":"first","affiliation":[{"name":"City of Hope National Medical Center , Duarte, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Alistar","sequence":"additional","affiliation":[{"name":"Atlantic Medical Group-Oncology Morristown Medical Center , Morristown, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Becerra","sequence":"additional","affiliation":[{"name":"Hoag Memorial Hospital , Newport Beach, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup","family":"Kasi","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center , Westwood, KS ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5136-5462","authenticated-orcid":false,"given":"Erkut","family":"Borazanci","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute , Scottsdale, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayle S","family":"Jameson","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute , Scottsdale, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise J","family":"Roe","sequence":"additional","affiliation":[{"name":"University of Arizona Cancer Center , Tucson, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy C","family":"Wertheim","sequence":"additional","affiliation":[{"name":"University of Arizona Cancer Center , Tucson, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Cridebring","sequence":"additional","affiliation":[{"name":"Translational Genomics Research Institute (TGen) A Part of City of Hope , Phoenix, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Truitt","sequence":"additional","affiliation":[{"name":"The Salk Institute\u00a0for Biological Studies , La Jolla, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Downes","sequence":"additional","affiliation":[{"name":"The Salk Institute\u00a0for Biological Studies , La Jolla, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T","family":"Barrett","sequence":"additional","affiliation":[{"name":"Mayo Clinic , Scottsdale, AZ ,","place":["United States"]},{"name":"Translational Genomics Research Institute An Affiliate of City of Hope , Flagstaff, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Korn","sequence":"additional","affiliation":[{"name":"Imaging Endpoints , Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keehoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Translational Genomics Research Institute An Affiliate of City of Hope , Flagstaff, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyong","family":"Han","sequence":"additional","affiliation":[{"name":"Translational Genomics Research Institute (TGen) A Part of City of Hope , Phoenix, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Evans","sequence":"additional","affiliation":[{"name":"The Salk Institute\u00a0for Biological Studies , La Jolla, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D","family":"Von Hoff","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute , Scottsdale, AZ ,","place":["United States"]},{"name":"Translational Genomics Research Institute (TGen) A Part of City of Hope , Phoenix, AZ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"2025031509010661700_CIT0001","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025031509010661700_CIT0002","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025031509010661700_CIT0003","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-018-0858-1","article-title":"Tumor microenvironment participates in metastasis of pancreatic cancer","volume":"17","author":"Ren","year":"2018","journal-title":"Mol Cancer"},{"key":"2025031509010661700_CIT0004","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3389\/fphys.2014.00244","article-title":"Vitamin D in inflammatory diseases","volume":"5","author":"W\u00f6bke","year":"2014","journal-title":"Front Physiol"},{"key":"2025031509010661700_CIT0005","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0038-9","article-title":"Exploring vitamin D metabolism and function in cancer","volume":"50","author":"Jeon","year":"2018","journal-title":"Exp Mol Med"},{"key":"2025031509010661700_CIT0006","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-14-1051","article-title":"Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer","volume":"21","author":"Whatcott","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2025031509010661700_CIT0007","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","article-title":"Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy","volume":"159","author":"Sherman","year":"2014","journal-title":"Cell"},{"key":"2025031509010661700_CIT0008","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.3390\/biom11111624","article-title":"The effects of Vitamin D on immune system and inflammatory diseases","volume":"11","author":"Ao","year":"2021","journal-title":"Biomolecules"},{"key":"2025031509010661700_CIT0009","doi-asserted-by":"publisher","first-page":"e100244","DOI":"10.1371\/journal.pone.0100244","article-title":"Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic","volume":"9","author":"Weiss","year":"2014","journal-title":"PLoS One"},{"key":"2025031509010661700_CIT0010","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2307\/2670170","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc."},{"key":"2025031509010661700_CIT0011","doi-asserted-by":"publisher","first-page":"97","DOI":"10.17691\/stm2021.13.2.11","article-title":"Radiomics and digital image texture analysis in oncology (review)","volume":"13","author":"Litvin","year":"2021","journal-title":"Sovrem Tekhnologii Med"},{"key":"2025031509010661700_CIT0012","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2217\/fmb-2023-0210","article-title":"Akkermansia muciniphila improves gastric cancer treatment by modulating the immune microenvironment","volume":"19","author":"Fang","year":"2024","journal-title":"Future Microbiol"},{"key":"2025031509010661700_CIT0013","author":"Zemplar Package Insert"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/1\/oyae323\/61587495\/oyae323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/1\/oyae323\/61587495\/oyae323.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T05:01:26Z","timestamp":1742014886000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae323\/7976614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae323","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]},"article-number":"oyae323"}}